£EPA¶EIA - ºAPMAKA ∂ÈÚfiÛıÂÙ·, ÔÈ ÊÈÌÚ¿Ù˜ ÌÔÚÔ‡Ó Ó· ¯ÚËÛÈÌÔÔÈËıÔ‡Ó ˆ˜ ÌÔÓÔıÂڷ›· Û ¿ÙÔÌ· Ì LDL ¯ÔÏËÛÙÂÚfiÏË ÎÔÓÙ¿ ÛÙÔ ÛÙfi¯Ô Ù˘ ıÂڷ›·˜ Ô˘ Ù·˘Ùfi¯ÚÔÓ· ÂÌÊ·Ó›˙Ô˘Ó ˘„ËÏ¿ ÙÚÈÁÏ˘ÎÂÚ›‰È· Î·È ¯·ÌËÏ¿ ›‰· ∏DL ¯ÔÏËÛÙÂÚfiÏ˘. Δ¤ÏÔ˜, ȉȷ›ÙÂÚ· ÛËÌ·ÓÙÈ΋ Â›Ó·È Ë ı¤ÛË ÙˆÓ ÊÈ-
ÌÚ·ÙÒÓ ÁÈ· ÙË Ì›ˆÛË ÙÔ˘ ˘ÔÏÂÈÔ̤ÓÔ˘ ÎÈÓ‰‡ÓÔ˘ ÌÂÙ¿ ÙËÓ Â›Ù¢ÍË Ì ÙË ¯ÔÚ‹ÁËÛË ÛÙ·Ù›Ó˘ ÙˆÓ ÛÙfi¯ˆÓ ÁÈ· ÙËÓ LDL ¯ÔÏËÛÙÂÚfiÏË, Ë ÔÔ›· ÂÍ·ÎÔÏÔ˘ı› Ó· ·ÔÙÂÏ› ÙÔÓ Î‡ÚÈÔ ÛÙfi¯Ô Ù˘ ˘ÔÏÈȉ·ÈÌÈ΋˜ ·ÁˆÁ‹˜. ™Â ·˘Ùfi ÙÔ Ï·›ÛÈÔ Ô ÚÔÛÂÎÙÈÎfi˜ Û˘Ó‰˘·ÛÌfi˜ Û¯ÂÙÈο ¯·ÌËÏ‹˜
‰fiÛ˘ ÛÙ·Ù›Ó˘ Ì ʷÈÓÔÊÈÌÚ¿ÙË Û ÂÈÏÂÁ̤ӷ ¿ÙÔÌ· ·Ó·Ì¤ÓÂÙ·È Ó· Û˘ÓÂÈÛʤÚÂÈ ÛÙËÓ ÂÚ·ÈÙ¤Úˆ Ì›ˆÛË ÙÔ˘ ηډȷÁÁÂÈ·ÎÔ‡ ÎÈÓ‰‡ÓÔ˘.
μÈ‚ÏÈÔÁÚ·Ê›· 1.
Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283-296
2.
Achimastos A, Liberopoulos E, Nikas S, et al. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002; 18: 59-63.
3.
4.
5.
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention
Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-418. 6.
7.
8.
Frick MH, Syvanne M, Nieminen MS, et al, for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96: 2137-2143. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-27. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
9.
Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronaryartery disease in type 2 diabetes. The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905-910.
10. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-1861 11. Keech AC, Mitchell P, Sumannen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687-1697. 12. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf M. Fibrateassociated adverse effects beyond muscle and liver toxicity. Curr Pharmaceut Des 2008; 14: in press.
15